Price
No data yet.
Social Signal Score
Analyst Ratings
28 analystsRevenue
$411.18M+60.83%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Stuart Essig
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 4,427
- Beta
- 1.28
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 1.31
Financials
Revenue
$411.18M+60.8%Net Income
$14.85M-47.4%EBITDA
$38.63M-36.0%Free Cash Flow
$85.73MEPS (diluted)
$0.19-45.7%Shares Outstanding (diluted)
78.58M-2.1%Operating Expenses
$187.21MCash & Debt
$311.93MReturn of Capital
$200.0KRevenue by Segment (annual)
$1.64BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.64B | $-516.47M | $-6.73 |
| 2024 | $1.61B | $-6.94M | $-0.09 |
| 2023 | $1.54B | $67.74M | $0.87 |
| 2022 | $1.56B | $180.55M | $2.18 |
| 2021 | $1.54B | $169.07M | $2.00 |
| 2020 | $1.37B | $133.89M | $1.58 |
| 2019 | $1.52B | $50.20M | $0.59 |
| 2018 | $1.47B | $60.80M | $0.73 |
| 2017 | $1.19B | $64.74M | $0.83 |
| 2016 | $992.08M | $74.56M | $1.00 |
| 2015 | $882.73M | $-3.52M | $-0.05 |
| 2014 | $928.30M | $34.00M | $0.52 |
| 2013 | $836.21M | $-16.98M | $-0.30 |
| 2012 | $830.87M | $41.20M | $0.74 |
Valuation
IARThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70+16.67%Social Signal Score
Mentions (22)
- Newsseekingalpha.com·12d ago·Positive
Integra LifeSciences Holdings Corporation (IART) Presents at 2026 UBS Global Healthcare Conference Transcript Integra LifeSciences Holdings Corporation (IART) Presents at 2026 UBS Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·30d ago·Negative
…on Is Getting Interesting Integra LifeSciences remains pressured by operational challenges, but restructuring and a returning CEO offer renewed turnaround potential. IART's Wound Reconstruction business continues to underperform, though upcoming product relaunches and market normalization could drive recovery. Valuation appears undemanding, with EBITDA margin expected to exceed 20% in 2025 and double-digit FCF margins possible by 2028.
View source ↗ - Newsseekingalpha.com·32d ago·Positive
Integra LifeSciences Holdings Corporation (IART) Q3 2026 Earnings Call Transcript Integra LifeSciences Holdings Corporation (IART) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·32d ago·Neutral
What Integra LifeSciences (IART) Said on Its Q3 Earnings Call Integra LifeSciences NASDAQ: IART reported third-quarter revenue at the low end of its guidance range as a flooding-related disruption at its Cincinnati facility and slower-than-expected Tissue Reconstruction performance weighed on results. The company said strength in neurosurgery and international Specialty Surgery partially offset those pressures.
View source ↗ - Newszacks.com·32d ago·Neutral
Integra (IART) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates Although the revenue and EPS for Integra (IART) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
View source ↗ - Newsglobenewswire.com·32d ago·Neutral
Integra LifeSciences Reports Third Quarter 2026 Financial Results PRINCETON, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2026.
View source ↗ - Newsglobenewswire.com·37d ago·Neutral
Integra LifeSciences to Highlight ENT and Instruments Portfolios and Sponsor New Clinical Research Presentations at AAO-HNSF 2026 Annual Meeting PRINCETON, N.J., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a global leader in medical technology, today announced its participation in the 2026 American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting & OTO EXPO, taking place October 17-20 in Los Angeles, California.
View source ↗ - Newsglobenewswire.com·47d ago·Neutral
Integra LifeSciences to Host Third Quarter 2026 Financial Results Conference Call on October 21, 2026 PRINCETON, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release third quarter 2026 financial results on Wednesday, October 21, 2026, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET.
View source ↗ - Newsglobenewswire.com·48d ago·Neutral
INTEGRA LIFESCIENCES HOLDINGS CORPORATION INVESTIGATION: IART Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in othe…
View source ↗ - Newsprnewswire.com·51d ago·Neutral
Integra LifeSciences Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Integra LifeSciences (IART) A $4.3 million to $6.3 million gap between Integra's preliminary third-quarter revenue and the Wall Street estimate sent IART shares lower. SueWallSt notifies investors of a pending investigation into potential securities claims for shareholders who lost money.
View source ↗ - Newsproactiveinvestors.com·51d ago·Positive
Integra LifeSciences lowers revenue and earnings outlook for 2026 Integra Lifesciences Holdings Corp (NASDAQ:IART) cut its 2026 revenue and adjusted earnings guidance after July flooding disrupted operations in Cincinnati, despite expectations for strong cash generation. The medical technology company now forecasts annual revenue of $1.634 billion to $1.654 billion, down from $1.654 billion to $1.695 billion.
View source ↗ - Newsglobenewswire.com·51d ago·Neutral
Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 Guidance PRINCETON, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today provided certain unaudited preliminary third quarter results and an update to its full-year 2026 guidance.
View source ↗ - Newsglobenewswire.com·51d ago·Negative
Integra LifeSciences Announces Launch of $600 Million Senior Secured Term Loan B PRINCETON, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced the launch of a proposed $600 million seven-year Senior Secured Term Loan B as part of a broader refinancing transaction.
View source ↗ - Newszacks.com·52d ago·Neutral
IART vs. PEN: Which Stock Is the Better Value Option? Investors interested in stocks from the Medical - Instruments sector have probably already heard of Integra LifeSciences (IART) and Penumbra (PEN). But which of these two stocks offers value investors a better bang for their buck right now?
View source ↗ - Newszacks.com·53d ago·Neutral
Should You Continue to Hold IART Stock in Your Portfolio? Integra sees steady Specialty Surgery demand and improving efficiency, but leverage and currency swings remain key challenges for Integra.
View source ↗ - Newszacks.com·54d ago·Positive
IART or PEN: Which Is the Better Value Stock Right Now? Investors interested in stocks from the Medical - Instruments sector have probably already heard of Integra LifeSciences (IART) and Penumbra (PEN). But which of these two companies is the best option for those looking for undervalued stocks?
View source ↗ - Newsglobenewswire.com·54d ago·Neutral
Integra LifeSciences Announces 100th Patient Enrolled in AERA® Pediatric Registry Prospective, multicenter registry advances toward planned enrollment of 300 pediatric patients Prospective, multicenter registry advances toward planned enrollment of 300 pediatric patients
View source ↗ - Newsglobenewswire.com·58d ago·Neutral
Integra LifeSciences Marks 20 Years of CUSA® Technology with Liver Surgery Education at ACS Clinical Congress 2026 Company to feature surgeon-led educational programming and technologies supporting liver surgery Company to feature surgeon-led educational programming and technologies supporting liver surgery
View source ↗ - Newsseekingalpha.com·68d ago·Positive
Integra LifeSciences Holdings Corporation (IART) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Integra LifeSciences Holdings Corporation (IART) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·81d ago·Positive
Integra LifeSciences: Strong Q2 2026 Results Support Recovery Thesis Integra LifeSciences Holdings is a turnaround story, maintaining a BUY rating after a strong 2Q26 earnings beat and margin expansion. IART's specialty surgery segment led revenue, while tissue reconstruction saw declines offset by a successful PriMatrix relaunch and upcoming SurgiMend reintroduction. Management targets leverage reduction to 2.5–3.5x by end-2026, prioritizing debt repayment as operating cash flow improves.
View source ↗ - Newszacks.com·94d ago·Neutral
Can IART's SurgiMend Relaunch Help Drive a Broader 2027 Recovery? Integra's SurgiMend relaunch could support a broader 2027 recovery, but customer recapture and FDA approval remain key to the upside.
View source ↗ - Newszacks.com·95d ago·Positive
Is IART Still Attractive as Its Low Valuation Meets Execution Risks? Integra's steep valuation discount meets margin gains and cost savings, but modest growth, leverage and unresolved FDA risks keep execution in focus.
View source ↗
Earnings
Thu, Feb 25(in 3 months)
Consensus estimate $0.69 per share
Typical surprise +5.9% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Oct 21$0.59 vs $0.56beat
- Wed, Jul 29$0.56 vs $0.48beat
- Tue, May 5$0.54 vs $0.41beat
- Thu, Feb 26$0.83 vs $0.79beat
- Thu, Oct 30$0.54 vs $0.43beat
- Thu, Jul 31$0.45 vs $0.43beat
Estimates and results for IART via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by IART officers and directors.
- Bought
- $102k
- Sold
- —
1 trade
0 trades
- Graves Jeffrey Abought
99 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Josh Gottheimerhouse · NJ05 · disclosed Jul 9, 2024 (21d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed May 15, 2024 (40d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Nov 11, 2023 (26d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Oct 15, 2023 (30d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Jul 11, 2023 (28d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Nov 5, 2020 (20d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Oct 13, 2020 (28d later)Sell$1,001 - $15,000
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (474d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Apr 16, 2020 (37d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Mar 16, 2020 (42d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Mar 10, 2020 (29d later)Buy$1,001 - $15,000
- Thomas Roland Tillissenate · NC · disclosed Feb 26, 2015 (13d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
